"There's No Heroin Around Anymore. It's All Fentanyl." Adaptation of an Opioid Overdose Prevention Counseling Approach to Address Fentanyl Overdose: Formative Study

Vanessa M McMahan, Justine Arenander, Tim Matheson, Audrey M Lambert, Sarah Brennan, Traci C Green, Alexander Y Walley, Phillip O Coffin, Vanessa M McMahan, Justine Arenander, Tim Matheson, Audrey M Lambert, Sarah Brennan, Traci C Green, Alexander Y Walley, Phillip O Coffin

Abstract

Background: Drug overdose mortality continues to increase, now driven by fentanyl. Prevention tools such as naloxone and medications to treat opioid use disorder are not sufficient to control overdose rates; additional strategies are urgently needed.

Objective: We sought to adapt a behavioral intervention to prevent opioid overdose (repeated-dose behavioral intervention to reduce opioid overdose [REBOOT]) that had been successfully piloted in San Francisco, California, United States, to the setting of Boston, Massachusetts, United States, and the era of fentanyl for a full efficacy trial.

Methods: We used the assessment, decision, adaptation, production, topical experts, integration, training, and testing (ADAPT-ITT) framework for intervention adaptation. We first identified opioid overdose survivors who were actively using opioids as the population of interest and REBOOT as the intervention to be adapted. We then performed theater testing and elicited feedback with 2 focus groups (n=10) in Boston in 2018. All participants had used opioids that were not prescribed to them in the past year and experienced an opioid overdose during their lifetime. We incorporated focus group findings into our initial draft of the adapted REBOOT intervention. The adapted intervention was reviewed by 3 topical experts, and their feedback was integrated into a subsequent draft. We trained study staff on the intervention and made final refinements based on internal piloting. This paper describes the overall ADAPT-ITT process for intervention adaptation, as well as a qualitative analysis of the focus groups. Working independently, 2 authors (VMM and JA) reviewed the focus group transcripts and coded them for salient and common themes using the constant comparison method, meeting to discuss any discrepancies until consensus was reached. Codes and themes were then mapped onto the REBOOT counseling steps.

Results: Focus group findings contributed to substantial changes in the counseling intervention to better address fentanyl overdose risk. Participants described the widespread prevalence of fentanyl and said that, although they tried to avoid it, avoidance was becoming impossible. Using alone and lower opioid tolerance were identified as contributors to overdose risk. Slow shots or tester shots were acceptable and considered effective to reduce risk. Naloxone was considered an effective reversal strategy. Although calling emergency services was not ruled out, participants described techniques to prevent the arrival of police on the scene. Expert review and internal piloting improved the intervention manual through increased participant centeredness, clarity, and usability.

Conclusions: We successfully completed the ADAPT-ITT approach for an overdose prevention intervention, using theater testing with people who use opioids to incorporate the perspectives of people who use drugs into a substance use intervention. In the current crisis, overdose prevention strategies must be adapted to the context of fentanyl, and innovative strategies must be deployed, including behavioral interventions.

Trial registration: ClinicalTrials.gov NCT03838510; https://ichgcp.net/clinical-trials-registry/NCT03838510.

Keywords: ADAPT-ITT; assessment, decision, adaptation, production, topical experts, integration, training, and testing; fentanyl; motivational interviewing; naloxone; opioid overdose; theater testing.

Conflict of interest statement

Conflicts of Interest: None declared.

©Vanessa M McMahan, Justine Arenander, Tim Matheson, Audrey M Lambert, Sarah Brennan, Traci C Green, Alexander Y Walley, Phillip O Coffin. Originally published in JMIR Formative Research (https://formative.jmir.org), 07.09.2022.

References

    1. Understanding the Epidemic. Centers for Disease Control and Prevention. 2021. Mar 17, [2021-05-04]. .
    1. Ciccarone D. The triple wave epidemic: supply and demand drivers of the US opioid overdose crisis. Int J Drug Policy. 2019 Sep;71:183–8. doi: 10.1016/j.drugpo.2019.01.010. S0955-3959(19)30018-0
    1. Zoorob M. Fentanyl shock: the changing geography of overdose in the United States. Int J Drug Policy. 2019 Aug;70:40–6. doi: 10.1016/j.drugpo.2019.04.010.S0955-3959(19)30113-6
    1. Ahmad FB, Cisewski JA, Rossen LM, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics. 2022. [2022-02-17]. .
    1. Mattson CL, Tanz LJ, Quinn K, Kariisa M, Patel P, Davis NL. Trends and geographic patterns in drug and synthetic opioid overdose deaths - United States, 2013-2019. MMWR Morb Mortal Wkly Rep. 2021 Feb 12;70(6):202–7. doi: 10.15585/mmwr.mm7006a4. doi: 10.15585/mmwr.mm7006a4.
    1. Bennett AS, Bell A, Tomedi L, Hulsey EG, Kral AH. Characteristics of an overdose prevention, response, and naloxone distribution program in Pittsburgh and Allegheny County, Pennsylvania. J Urban Health. 2011 Dec;88(6):1020–30. doi: 10.1007/s11524-011-9600-7.
    1. Walley AY, Xuan Z, Hackman HH, Quinn E, Doe-Simkins M, Sorensen-Alawad A, Ruiz S, Ozonoff A. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013 Jan 30;346:f174. doi: 10.1136/bmj.f174.
    1. Maxwell S, Bigg D, Stanczykiewicz K, Carlberg-Racich S. Prescribing naloxone to actively injecting heroin users: a program to reduce heroin overdose deaths. J Addict Dis. 2006;25(3):89–96. doi: 10.1300/J069v25n03_11.
    1. Lankenau SE, Wagner KD, Silva K, Kecojevic A, Iverson E, McNeely M, Kral AH. Injection drug users trained by overdose prevention programs: responses to witnessed overdoses. J Community Health. 2013 Feb;38(1):133–41. doi: 10.1007/s10900-012-9591-7.
    1. Wheeler E, Jones TS, Gilbert MK, Davidson PJ, Centers for Disease Control and Prevention (CDC) Opioid overdose prevention programs providing naloxone to laypersons - United States, 2014. MMWR Morb Mortal Wkly Rep. 2015 Jun 19;64(23):631–5. mm6423a2
    1. Coffin PO, Maya S, Kahn JG. Modeling of overdose and naloxone distribution in the setting of fentanyl compared to heroin. Drug Alcohol Depend. 2022 Jul 01;236:109478. doi: 10.1016/j.drugalcdep.2022.109478.S0376-8716(22)00215-0
    1. Strang J, McDonald R, Alqurshi A, Royall P, Taylor D, Forbes B. Naloxone without the needle - systematic review of candidate routes for non-injectable naloxone for opioid overdose reversal. Drug Alcohol Depend. 2016 Jun 01;163:16–23. doi: 10.1016/j.drugalcdep.2016.02.042.S0376-8716(16)00141-1
    1. Bohnert AS, Bonar EE, Cunningham R, Greenwald MK, Thomas L, Chermack S, Blow FC, Walton M. A pilot randomized clinical trial of an intervention to reduce overdose risk behaviors among emergency department patients at risk for prescription opioid overdose. Drug Alcohol Depend. 2016 Jun 01;163:40–7. doi: 10.1016/j.drugalcdep.2016.03.018.S0376-8716(16)30005-9
    1. Coffin PO, Santos GM, Matheson T, Behar E, Rowe C, Rubin T, Silvis J, Vittinghoff E. Behavioral intervention to reduce opioid overdose among high-risk persons with opioid use disorder: a pilot randomized controlled trial. PLoS One. 2017 Oct 19;12(10):e0183354. doi: 10.1371/journal.pone.0183354. PONE-D-17-19991
    1. Wingood GM, DiClemente RJ. The ADAPT-ITT model: a novel method of adapting evidence-based HIV interventions. J Acquir Immune Defic Syndr. 2008 Mar 01;47 Suppl 1:S40–6. doi: 10.1097/QAI.0b013e3181605df1.00126334-200803011-00008
    1. Staton M, Knudsen HK, Walsh SL, Oser C, Pike E, Lofwall M. Adaptation of a standard extended-release naltrexone (XR-NTX) protocol for rural re-entering offenders with OUD. Health Justice. 2021 Feb 05;9(1):4. doi: 10.1186/s40352-021-00130-0. doi: 10.1186/s40352-021-00130-0.10.1186/s40352-021-00130-0
    1. Cochran G, Gordon AJ, Field C, Bacci J, Dhital R, Ylioja T, Stitzer M, Kelly T, Tarter R. Developing a framework of care for opioid medication misuse in community pharmacy. Res Social Adm Pharm. 2016;12(2):293–301. doi: 10.1016/j.sapharm.2015.05.001. S1551-7411(15)00081-9
    1. Coffin PO, Tracy M, Bucciarelli A, Ompad D, Vlahov D, Galea S. Identifying injection drug users at risk of nonfatal overdose. Acad Emerg Med. 2007 Jul;14(7):616–23. doi: 10.1197/j.aem.2007.04.005. j.aem.2007.04.005
    1. Piper TM, Rudenstine S, Stancliff S, Sherman S, Nandi V, Clear A, Galea S. Overdose prevention for injection drug users: lessons learned from naloxone training and distribution programs in New York City. Harm Reduct J. 2007 Jan 25;4:3. doi: 10.1186/1477-7517-4-3. 1477-7517-4-3
    1. Somerville NJ, O'Donnell J, Gladden RM, Zibbell JE, Green TC, Younkin M, Ruiz S, Babakhanlou-Chase H, Chan M, Callis BP, Kuramoto-Crawford J, Nields HM, Walley AY. Characteristics of fentanyl overdose - Massachusetts, 2014-2016. MMWR Morb Mortal Wkly Rep. 2017 Apr 14;66(14):382–6. doi: 10.15585/mmwr.mm6614a2. doi: 10.15585/mmwr.mm6614a2.
    1. The Massachusetts Opioid Epidemic: An Issue of Substance. Massachusetts Taxpayers Foundation. 2018. Nov, [2021-05-04]. .
    1. Pardo B, Taylor J, Caulkins JP, Kilmer B, Reuter P, Stein BD. Understanding America's Surge in Fentanyl and Other Synthetic Opioids. RAND Corporation. 2019. [2021-07-14]. .
    1. Rev. [2021-06-21].
    1. Glaser BG. The constant comparative method of qualitative analysis. Grounded Theory Rev. 1965 Apr 1;12(4):436–45.
    1. Bowles JM, Smith LR, Verdugo SR, Wagner KD, Davidson PJ. "Generally, you get 86'ed because you're a liability": an application of Integrated Threat Theory to frequently witnessed overdoses and social distancing responses. Soc Sci Med. 2020 Sep;260:113190. doi: 10.1016/j.socscimed.2020.113190. S0277-9536(20)30409-3
    1. Kahn LS, Wozniak M, Vest BM, Moore C. "Narcan encounters:" overdose and naloxone rescue experiences among people who use opioids. Subst Abus. 2022;43(1):113–26. doi: 10.1080/08897077.2020.1748165.
    1. Urmanche AA, Beharie N, Harocopos A. Fentanyl preference among people who use opioids in New York City. Drug Alcohol Depend. 2022 Aug 01;237:109519. doi: 10.1016/j.drugalcdep.2022.109519.S0376-8716(22)00256-3
    1. McLean K, Monnat SM, Rigg K, Sterner 3rd GE, Verdery A. "You never know what you're getting": opioid users' perceptions of fentanyl in Southwest Pennsylvania. Subst Use Misuse. 2019;54(6):955–66. doi: 10.1080/10826084.2018.1552303.
    1. Rowe C, Santos GM, Behar E, Coffin PO. Correlates of overdose risk perception among illicit opioid users. Drug Alcohol Depend. 2016 Feb 01;159:234–9. doi: 10.1016/j.drugalcdep.2015.12.018. S0376-8716(15)01833-5
    1. Behar E, Chang JS, Countess K, Matheson T, Santos GM, Coffin P. Perceived causes of personal versus witnessed overdoses among people who inject opioids. Subst Use Misuse. 2019;54(12):1929–37. doi: 10.1080/10826084.2019.1609988.
    1. Goldman JE, Waye KM, Periera KA, Krieger MS, Yedinak JL, Marshall BD. Perspectives on rapid fentanyl test strips as a harm reduction practice among young adults who use drugs: a qualitative study. Harm Reduct J. 2019 Jan 08;16(1):3. doi: 10.1186/s12954-018-0276-0. 10.1186/s12954-018-0276-0
    1. Bennett AS, Freeman R, Des Jarlais DC, Aronson ID. Reasons people who use opioids do not accept or carry no-cost naloxone: qualitative interview study. JMIR Form Res. 2020 Dec 23;4(12):e22411. doi: 10.2196/22411. v4i12e22411
    1. Bennett AS, Scheidell J, Bowles JM, Khan M, Roth A, Hoff L, Marini C, Elliott L. Naloxone protection, social support, network characteristics, and overdose experiences among a cohort of people who use illicit opioids in New York City. Harm Reduct J. 2022 Mar 04;19(1):20. doi: 10.1186/s12954-022-00604-w. 10.1186/s12954-022-00604-w
    1. Latimore AD, Bergstein RS. "Caught with a body" yet protected by law? Calling 911 for opioid overdose in the context of the Good Samaritan Law. Int J Drug Policy. 2017 Dec;50:82–9. doi: 10.1016/j.drugpo.2017.09.010.S0955-3959(17)30288-8
    1. Wagner KD, Harding RW, Kelley R, Labus B, Verdugo SR, Copulsky E, Bowles JM, Mittal ML, Davidson PJ. Post-overdose interventions triggered by calling 911: centering the perspectives of people who use drugs (PWUDs) PLoS One. 2019 Oct 17;14(10):e0223823. doi: 10.1371/journal.pone.0223823. PONE-D-19-17411
    1. Davidson PJ, Ochoa KC, Hahn JA, Evans JL, Moss AR. Witnessing heroin-related overdoses: the experiences of young injectors in San Francisco. Addiction. 2002 Dec;97(12):1511–6. doi: 10.1046/j.1360-0443.2002.00210.x.210
    1. Tracy M, Piper TM, Ompad D, Bucciarelli A, Coffin PO, Vlahov D, Galea S. Circumstances of witnessed drug overdose in New York City: implications for intervention. Drug Alcohol Depend. 2005 Aug 01;79(2):181–90. doi: 10.1016/j.drugalcdep.2005.01.010.S0376-8716(05)00050-5
    1. Durieux J, Curtis A, Mirka M, Jefferis E, Felix C, Essel B. An exploration of Narcan as a harm reduction strategy and user's attitudes toward law enforcement involvement in overdose cases. Int J Environ Res Public Health. 2022 Mar 08;19(6):3149. doi: 10.3390/ijerph19063149. ijerph19063149
    1. Ataiants J, Mazzella S, Roth AM, Sell RL, Robinson LF, Lankenau SE. Overdose response among trained and untrained women with a history of illicit drug use: a mixed-methods examination. Drugs (Abingdon Engl) 2021;28(4):328–39. doi: 10.1080/09687637.2020.1818691.
    1. Rochester E, Graboyes M. Experiences of people who use drugs with naloxone administration: a qualitative study. Drugs (Abingdon Engl) 2022;29(1):54–61. doi: 10.1080/09687637.2020.1855116.
    1. van der Meulen E, Chu SK, Butler-McPhee J. "That's why people don't call 911": ending routine police attendance at drug overdoses. Int J Drug Policy. 2021 Feb;88:103039. doi: 10.1016/j.drugpo.2020.103039.S0955-3959(20)30377-7
    1. Opioid overdose basics: responding to an opioid overdose. National Harm Reduction Coalition. 2020. Sep 1, [2022-06-09].
    1. Morse JM. Determining sample size. Qual Health Res. 2000 Jan 01;10(1):3–5. doi: 10.1177/104973200129118183.
    1. Latkin CA, Edwards C, Davey-Rothwell MA, Tobin KE. The relationship between social desirability bias and self-reports of health, substance use, and social network factors among urban substance users in Baltimore, Maryland. Addict Behav. 2017 Oct;73:133–6. doi: 10.1016/j.addbeh.2017.05.005. S0306-4603(17)30175-2
    1. Harris MT, Bagley SM, Maschke A, Schoenberger SF, Sampath S, Walley AY, Gunn CM. Competing risks of women and men who use fentanyl: "the number one thing I worry about would be my safety and number two would be overdose". J Subst Abuse Treat. 2021 Jun;125:108313. doi: 10.1016/j.jsat.2021.108313. S0740-5472(21)00039-8

Source: PubMed

3
Abonneren